Navigation Links
Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next-Generation Everolimus Stent
Date:9/18/2009

. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings, product performance and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looki
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Boston Scientifics Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network
2. Boston Scientific Statement on the Passing of Senator Edward Kennedy
3. Boston Scientific to Webcast Conference Call Discussing Results of Landmark MADIT-CRT Trial
4. Boston University Periodontal Study on Imagenetix Compound Published in The Journal of Periodontology
5. Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System
6. Boston Scientific to Participate in Wachovia Conference
7. Boston Scientifics SpyGlass(R) Direct Visualization System Featured in Broad Range of Clinical Studies at Upcoming Digestive Disease Week(R)
8. FDA Clears Boston Scientifics SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System
9. FDA Approves Boston Scientifics Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
10. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
11. Boston Scientific Welcomes Launch of Syntax Score Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... and OSAKA, Japan , April ... Application (CiRA) of Kyoto University and Takeda Pharmaceutical ... work together to develop clinical applications of induced ... failure, diabetes mellitus, neurological disorders and cancer immunotherapy. ... (T-CiRA) is designed to expedite multiple research projects ...
(Date:4/16/2015)... 16, 2015  Schulman Associates IRB, Inc., the industry-leading ... a long-term lease on Laboratory Drive in the heart ... . The location will house review board and service ... quality reviews and customer service to clients. ... Schulman in the deal, while Capital Associates Management, LLC ...
(Date:4/16/2015)... , April 16, 2015  In recognition of World ... with hemophilia advocacy groups to illuminate more than 15 prominent ... including Boston,s Zakim Bridge and Prudential ... New Orleans, Mercedes-Benz Superdome and Denver,s ... during the evening of April 17, and coincide with hemophilia ...
(Date:4/16/2015)... 2015 A new infographic compiles useful ... research institutions to learn how Appleā€™s new framework can ... timing is ideal since Apple made Research Kit ... an open-source framework for developing medical research apps that ... for researchers to collect secure clinical data and communicate ...
Breaking Biology Technology:CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3
... DNDN ) today announced the Medicare Evidence ... of labeled and unlabeled use of PROVENGE® (sipuleucel-T) treatment ... This panel was convened as a part of the ... Centers for Medicare and Medicaid Services (CMS).   ...
... ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) ... CTI,s Pixuvri (pixantrone dimaleate) Pediatric Investigation Plan ("PIP") for ... children between the ages of six months and 18 ... EMA adopted an opinion agreeing to the PIP and ...
Cached Biology Technology:Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence 2Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence 3Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 2Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 3Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 4Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 5Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 6Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 7Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 8Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 9Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 10European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri 2European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri 3
(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
(Date:3/23/2015)... Mass , March 23, 2015 SoundView Technology ... of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was ... user feedback on their experience with the Wocket in multiple ... at CVS, Whole Foods and other retailers, making both debit ... Kris Tuttle also says, "If the company meets their ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... Saskatchewan's Vaccine and Infectious Disease Organization (VIDO) have developed a ... fight against a disease for which no vaccines are yet ... that this vaccination technique may be effective against HCV. The ... , The team, funded by the Canadian Institutes of ...
... and the Department of Horticulture in the College ... have developed a new procedure for the efficient ... of strawberry. The scientists have used Agrobacterium tumefaciens, ... woodland or alpine strawberry Fragaria vesca. , ...
... of molecule which they believe could ultimately lead to ... modified tobacco. Writing in Plant Biotechnology Journal, Dr Patricia ... along with researchers at the University of Warwick say ... far frustrated attempts to turn plants into economically viable ...
Cached Biology News:U of S researchers develop new vaccine candidate against hepatitis C 2Strawberries by design 2Do plants have the potential to vaccinate against HIV? 2
... Agencourt offers pre-validated ... over 1500 amplicons within ... serine/threonin kinases, and more ... These assays were ...
... 384-Well Microarray plates are ideal for use as ... liquid handling applications (down to 5µl). These plates ... well design. Features 384 ... available 70µl well volume (cylindrical well), 55µl ...
Anti-Phospho-JKK/SEK1/MKK4 pAb Description: 100 g rabbit polyclonal antibody. Reacts with human/mouse/rat. Tested in WB. Research Focus: signal transduction Storage: -20C Shipping Tem...
...
Biology Products: